Related coverage linked through entity extraction aliases.
Aug 19, 2026
A study in Health and Quality of Life Outcomes found speech dysfunction is the dominant early determinant of postoperative quality of life in oral cancer patients, with significant direct and indirect effects through psychosocial pathways.
Feb 19, 2026
A comprehensive market report reveals over 180 companies are developing more than 200 PD-1 and PD-L1 inhibitor drugs, with recent fast-track designations and successful Phase III trial results driving expansion in cancer immunotherapy.
Feb 23, 2026
Two clinical trials demonstrate efficacy of talimogene laherparepvec (T-VEC) oncolytic virus therapy in HER2-negative breast cancer and nonmelanoma skin cancers, with favorable safety profiles and durable responses in subset of patients.
